Physician profile
William Robert Schetman
NPI 1427020874
$11,411.94
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,175 · 2020: $1,413 · 2021: $3,262 · 2022: $2,803 · 2023: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,382.36 | 2019-2023 | Mounjaro, Jardiance, Reyvow |
| Biohaven Pharmaceuticals, INC. | $1,281.18 | 2020-2021 | |
| Abbvie INC. | $1,279.42 | 2019-2023 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $789.22 | 2019-2022 | |
| Novo Nordisk INC | $785.64 | 2019-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $571.59 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $544.83 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $538.87 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $523.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $507.50 | 2019-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $493.55 | 2019-2023 | Verquvo, Belsomra |
| Amgen INC. | $415.79 | 2019-2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $311.93 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.31 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.47 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schetman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.